Jean Bergeron

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

Hypertriglyceridemic Waist

Isabelle Lemieux, Agnès Pascot, Charles Couillard et al. · Circulation · 2000 · 930 citations · Full text

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Evan A. Stein, Dan Gipe, Jean Bergeron et al. · The Lancet · 2012 · 575 citations

Metabolic Syndrome, Cardiovascular Disease, Stable Statin Dose +7

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon et al. · Journal of clinical lipidology · 2015 · 460 citations · Full text

Race, Visceral Adipose Tissue, Plasma Lipids, and Lipoprotein Lipase Activity in Men and Women

Jean‐Pierre Després, Charles Couillard, Jacques Gagnon et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2000 · 384 citations

Nutrition, Visceral Adipose Tissue, Cardiometabolic Risk +21